Molecular features of malignant gastric tumors

Gastric cancer is one of the most widespread cancers and makes a significant contribution to the global mortality rate from malignant neoplasms. The late onset of clinical symptoms is the main reason why the disease is often diagnosed at an advanced stage, and this limits the available therapeutic approaches. Despite the fact, that extensive studies have been carried out to identify the mechanisms and markers of the development and progression of the disease, their results are currently not fully included in clinical practice. As a consequence, only marginal improvement in long-term survival has been achieved and patient prognosis remains poor. Understanding the molecular genetic features of gastric malignant tumors can provide insight into their pathogenesis, help identify new biomarkers for prognosis and diagnosis, and identify new therapeutic targets. In recent decades, advances in high throughput sequencing technologies have improved understanding of the molecular genetic aspects of gastric cancer. This review considers molecular level changes, including information on tumor suppressor genes, oncogenes, cell cycle and apoptosis regulators, cell adhesion molecules, loss of heterozygosity, micro-satellite instability and epigenetic aberrations (change in methylation level and modification of histones). The review is also devoted to the molecular aspects of pathogenesis – changes in the signaling pathways involved in the gastric cancer development; the classification of sporadic and hereditary gastric cancer at the molecular genetic level is considered. The characteristics and classification of GC presented in this review at the genetic and epigenetic levels confirms that this disease is heterogeneous. These data can be used both to develop and test potential markers and new targeted therapeutic approaches.

1. Kit OI, Gevorkyan YUA, Frantsiyants EM, Dashkov AV, Soldatkina NV, Ilchenko SA, et al. Results of chemotherapy with ozonized media in complex treatment sick of resectable gastric cancer. Modern Problems of Science and Education. 2012;(6):172. (In Russ.). EDN: TODMQF

2. Fujino Y, Tamakoshi A, Ohno Y, Mizoue T, Tokui N, Yoshimura T, et al. Prospective study of educational background and stom- ach cancer in Japan. Prev Med. 2002 Aug;35(2):121–127. https://doi.org/10.1006/pmed.2002.1066

3. Kit OI, Samoylenko NS, Frantsiyants EM, Soldatkina NV, Sagakyants AB, Kharagezov DA, et al. Gastric cancer: modern directions in basic research. Modern problems of science and education. 2019;(4):136. (In Russ.). EDN: QRPQPE

4. Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012 Jul 15;4(7):156–169. https://doi.org/10.4251/wjgo.v4.i7.156

5. Marqués-Lespier JM, González-Pons M, Cruz-Correa M. Current Perspectives on Gastric Cancer. Gastroenterol Clin North Am. 2016 Sep;45(3):413–428. https://doi.org/10.1016/j.gtc.2016.04.002

6. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Na- ture. 2014 Sep 11;513(7517):202–209. https://doi.org/10.1038/nature13480

7. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015 May;21(5):449–456. https://doi.org/10.1038/nm.3850

8. Li X, Wu WKK, Xing R, Wong SH, Liu Y, Fang X, et al. Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability. Cancer Res. 2016 Apr 1;76(7):1724–1732. https://doi.org/10.1158/0008-5472.CAN-15-2443

9. Geddert H, zur Hausen A, Gabbert HE, Sarbia M. EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is asso- ciated with promoter methylation of p16, p14 and APC, but not hMLH1. Cell Oncol (Dordr). 2011 Jun;34(3):209–214. https://doi.org/10.1007/s13402-011-0028-6

10. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012 May;61(5):673– 684. https://doi.org/10.1136/gutjnl-2011-301839

11. Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, et al. Molecular Heterogeneity and Recep- tor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov. 2015 Dec;5(12):1271–1281. https://doi.org/10.1158/2159-8290.CD-15-0748

12. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new par- adigm. Clin Cancer Res. 2011 May 1;17(9):2693–2701. https://doi.org/10.1158/1078-0432.CCR-10-2203

13. Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010 Apr;8(4):437–447. https://doi.org/10.6004/jnccn.2010.0033

14. Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, et al. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Ann Oncol. 2016 Jan;27(1):127. https://doi.org/10.1093/annonc/mdv508

15. Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 2015 Apr;18(2):227–238. https://doi.org/10.1007/s10120-014-0360-4

16. Yuki S, Shitara K, Kadowaki S, Minashi K, Takeno A, Hara H, et al. The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC). JCO. 2018 May 20;36(15_suppl):4050–4050. https://doi.org/10.1200/JCO.2018.36.15_suppl.4050

17. Kutilin DS, Airapetova TG, Anistratov PA, Pyltsin SP, Leiman IA, Karnaukhov NS, et al. Copy Number Variation in Tumor Cells and Extracellular DNA in Patients with Lung Adenocarcinoma. Bull Exp Biol Med. 2019 Oct;167(6):771–778. https://doi.org/10.1007/s10517-019-04620-y

18. Kit OI, Vodolazhsky DI, Kutilin DS, Gudueva EN. Changes in the number of copies of genetic loci in gastric cancer. Mol Biol (Mosk). 2015;49(4):658–666. https://doi.org/10.7868/S0026898415040096

19. Kit OI, Vodolazhsky DI, Gevorkyan YuA, Kutilin DS, Maleyko ML, Dvadnenko KV, et al. Changes in the relative copy number of oct4 and sox2 genes in malignancy of gastric tissue. Fundamental Studies. 2014;(10-4):671–674. (In Russ.). EDN: SVQVMB

20. Kit OI, Vodolazhsky DI, Kutilin DS, Maleyko ML, Dvadnenko KV, Enin YaS, et al. The copyicity of the GSTP1, NFKB1 and HV2 genes of mitochondrial DNA in some histological types of gastric cancer. The successes of modern natural science. 2015;(1- 6):918–921. (In Russ.). EDN: TSNHUH

21. Kit OI, Vodolazhsky DI, Kutilin DS, Maleyko ML, Dvadnenko KV, Enin YaS, et al. Relative copyicity of apoptosis – regulating genes as an indicator of malignancy of stomach tissues. The successes of modern natural science. 2015;(3):40–45. (In Russ.). EDN: UDZVXH

22. Kutilin DS, Vodolazhsky DI, Trifanov VS, Przhedetsky YuV. Relative copy number variation of genes in malignant gastric tissues. Journal of Clinical Oncology. 2015 May 20;33:e15033–e15033. https://doi.org/10.1200/jco.2015.33.15_suppl.e15033

23. Kit OI, Kutilin DS, Vodolazhsky DI, Maleyko ML, Dvadnenko KV, Antonets AV, et al. Changes in the copyicity of genes during malignancy of stomach tissues. Eurasian Journal of Oncology. 2014;3(3):436–437. (In Russ.). EDN: TJNRQM

24. Li-Chang HH, Kasaian K, Ng Y, Lum A, Kong E, Lim H, et al. Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer. 2015 Feb 6;15:32. https://doi.org/10.1186/s12885-015-1021-7

25. Hu XT, He C. Recent progress in the study of methylated tumor suppressor genes in gastric cancer. Chin J Cancer. 2013 Jan;32(1):31–41. https://doi.org/10.5732/cjc.011.10175

26. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011 Oct 30;43(12):1219–1223. https://doi.org/10.1038/ng.982

27. Wang K, Yuen ST, Xu J, Lee SP, Yan HHN, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014 Jun;46(6):573–582. https://doi.org/10.1038/ng.2983

28. Katoh M, Katoh M. Evolutionary recombination hotspot around GSDML-GSDM locus is closely linked to the oncogenomic recombination hotspot around the PPP1R1B-ERBB2-GRB7 amplicon. Int J Oncol. 2004 Apr;24(4):757–763.

29. Gonzalgo ML, Jones PA. Mutagenic and epigenetic effects of DNA methylation. Mutat Res. 1997 Apr;386(2):107–118. https://doi.org/10.1016/s1383-5742(96)00047-6

30. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003 May;200(1):39–46. https://doi.org/10.1002/path.1288

31. Wu XX, Li H, Zhao M. Medical Molecular Biology Beijing: Science Press; 2009, 303–304 p.

32. Calcagno DQ, Leal MF, Assumpcao PP, Smith MAC, Burbano RR. MYC and gastric adenocarcinoma carcinogenesis. World J Gastroenterol. 2008 Oct 21;14(39):5962–5968. https://doi.org/10.3748/wjg.14.5962

33. Song Z, Liu W, Xiao Y, Zhang M, Luo Y, Yuan W, et al. PRR11 Is a Prognostic Marker and Potential Oncogene in Patients with Gastric Cancer. PLoS One. 2015;10(8):e0128943. https://doi.org/10.1371/journal.pone.0128943

34. Kishimoto I, Mitomi H, Ohkura Y, Kanazawa H, Fukui N, Watanabe M. Abnormal expression of p16(INK4a), cyclin D1, cy- clin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas. J Surg Oncol. 2008 Jul 1;98(1):60–66. https://doi.org/10.1002/jso.21087

35. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994 Apr 15;73(8):2013– 2026. https://doi.org/10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j

36. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999 Aug 1;13(15):1899–1911. https://doi.org/10.1101/gad.13.15.1899

37. Guo XY, Dong L, Qin B, Jiang J, Shi AM. Decreased expression of gastrokine 1 in gastric mucosa of gastric cancer patients. World J Gastroenterol. 2014 Nov 28;20(44):16702–16706. https://doi.org/10.3748/wjg.v20.i44.16702

38. Mao W, Chen J, Peng TL, Yin XF, Chen LZ, Chen MH. Helicobacter pylori infection and administration of non-steroi- dal anti-inflammatory drugs down-regulate the expression of gastrokine-1 in gastric mucosa. Turk J Gastroenterol. 2012 Jun;23(3):212–219. https://doi.org/10.4318/tjg.2012.0345

39. Yan GR, Xu SH, Tan ZL, Yin XF, He QY. Proteomics characterization of gastrokine 1-induced growth inhibition of gastric can- cer cells. Proteomics. 2011 Sep;11(18):3657–3664. https://doi.org/10.1002/pmic.201100215

40. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, Fukamachi H, et al. Synergistic tumour suppressor activity of E-cad- herin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut. 2012 Mar;61(3):344–353. https://doi.org/10.1136/gutjnl-2011-300050

41. Chun N, Ford JM. Genetic testing by cancer site: stomach. Cancer J. 2012;18(4):355–363. https://doi.org/10.1097/PPO.0b013e31826246dc

42. Chen Y, Kingham K, Ford JM, Rosing J, Van Dam J, Jeffrey RB, et al. A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol. 2011 Sep;18(9):2594–2598. https://doi.org/10.1245/s10434-011-1648-9

43. Van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric can- cer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015 Jun;52(6):361–374. https://doi.org/10.1136/jmedgenet-2015-103094

44. Chen J, Wang T, Zhou YC, Gao F, Zhang ZH, Xu H, et al. Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer. J Exp Clin Cancer Res. 2014 May 3;33(1):38. https://doi.org/10.1186/1756-9966-33-38

45. Kannan A, Krishnan A, Ali M, Subramaniam S, Halagowder D, Sivasithamparam ND. Caveolin-1 promotes gastric cancer pro- gression by up-regulating epithelial to mesenchymal transition by crosstalk of signalling mechanisms under hypoxic condition. Eur J Cancer. 2014 Jan;50(1):204–215. https://doi.org/10.1016/j.ejca.2013.08.016

46. Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY, Liang AB, et al. CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci. 2012;13(5):6399–6406. https://doi.org/10.3390/ijms13056399

47. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology. 2012 Sep;143(3):550–563. https://doi.org/10.1053/j.gastro.2012.07.009

48. Karaman A, Kabalar ME, Binici DN, Oztürk C, Pirim I. Genetic alterations in gastric precancerous lesions. Genet Couns. 2010;21(4):439–450.

49. Byun DS, Cho K, Ryu BK, Lee MG, Park JI, Chae KS, et al. Frequent monoallelic deletion of PTEN and its reciprocal associatio- in with PIK3CA amplification in gastric carcinoma. Int J Cancer. 2003 Apr 10;104(3):318–327. https://doi.org/10.1002/ijc.10962

50. Rumpel CA, Powell SM, Moskaluk CA. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol. 1999 May;154(5):1329–1334. https://doi.org/10.1016/S0002-9440(10)65386-2

51. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol. 2006 Jun;17 Suppl 7:vii97–102. https://doi.org/10.1093/annonc/mdl960

52. Skierucha M, Milne AN, Offerhaus GJA, Polkowski WP, Maciejewski R, Sitarz R. Molecular alterations in gastric cancer with special reference to the early-onset subtype. World J Gastroenterol. 2016 Feb 28;22(8):2460–2474. https://doi.org/10.3748/wjg.v22.i8.2460

53. Benusiglio PR, Malka D, Rouleau E, De Pauw A, Buecher B, Noguès C, et al. CDH1 germline mutations and the hereditary dif- fuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet. 2013 Jul;50(7):486–489. https://doi.org/10.1136/jmedgenet-2012-101472

54. Nobili S, Bruno L, Landini I, Napoli C, Bechi P, Tonelli F, et al. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol. 2011 Jan 21;17(3):290–299. https://doi.org/10.3748/wjg.v17.i3.290

55. Simpson AJ, Caballero OL, Pena SD. Microsatellite instability as a tool for the classification of gastric cancer. Trends Mol Med. 2001 Feb;7(2):76–80. https://doi.org/10.1016/s1471-4914(01)01916-5

56. Hirst M, Marra MA. Epigenetics and human disease. Int J Biochem Cell Biol. 2009 Jan;41(1):136–146. https://doi.org/10.1016/j.biocel.2008.09.011

57. Chan AWH, Chan MWY, Lee TL, Ng EKW, Leung WK, Lau JYW, et al. Promoter hypermethylation of Death-associated pro- tein-kinase gene associated with advance stage gastric cancer. Oncol Rep. 2005 May;13(5):937–941.

58. Dimitriadi TA, Burtsev DV, Dzhenkova EA, Kutilin DS. Differential expression of microRNAs and their target genes in cervical intraepithelial neoplasias of varying severity. Advances in Molecular Oncology. 2020;7(2):47–61. (In Russ.). https://doi.org/10.17650/2313-805X-2020-7-2-47-61, EDN: NNFZRI

59. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol. 2008 Oct;68(1):1–11. https://doi.org/10.1016/j.critrevonc.2008.03.001

60. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015 Feb;16(2):e60–70. https://doi.org/10.1016/S1470-2045(14)71016-2

61.